BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25649952)

  • 21. Characterization of a point mutation in the parC gene of Mycoplasma bovirhinis associated with fluoroquinolone resistance.
    Hirose K; Kawasaki Y; Kotani K; Abiko K; Sato H
    J Vet Med B Infect Dis Vet Public Health; 2004 May; 51(4):169-75. PubMed ID: 15228551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to fluoroquinolones linked to gyrA and par C mutations and overexpression of acr AB efflux pump in Salmonella enterica serotype Choleraesuis.
    Chu C; Su LH; Chu CH; Baucheron S; Cloeckaert A; Chiu CH
    Microb Drug Resist; 2005; 11(3):248-53. PubMed ID: 16201927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro.
    Hansen H; Heisig P
    Microb Drug Resist; 2003; 9(1):25-32. PubMed ID: 12705680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
    Misiurina OIu; Shipitsina EV; Finashutina IuP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
    Mol Gen Mikrobiol Virusol; 2004; (3):3-7. PubMed ID: 15354934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
    Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
    Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-existence of plasmid-mediated quinolone resistance determinants and mutations in gyrA and parC among fluoroquinolone-resistant clinical Enterobacteriaceae isolated in a tertiary hospital in Warsaw, Poland.
    Piekarska K; Wołkowicz T; Zacharczuk K; Rzeczkowska M; Chróst A; Bareja E; Olak M; Gierczyński R
    Int J Antimicrob Agents; 2015 Mar; 45(3):238-43. PubMed ID: 25468717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolone resistance mechanisms of Shigella flexneri isolated in Bangladesh.
    Azmi IJ; Khajanchi BK; Akter F; Hasan TN; Shahnaij M; Akter M; Banik A; Sultana H; Hossain MA; Ahmed MK; Faruque SM; Talukder KA
    PLoS One; 2014; 9(7):e102533. PubMed ID: 25028972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008.
    Yang H; Duan G; Zhu J; Zhang W; Xi Y; Fan Q
    Int J Antimicrob Agents; 2013 Aug; 42(2):173-7. PubMed ID: 23796894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug-Resistant Aeromonas veronii Recovered from Channel Catfish (Ictalurus punctatus) in China: Prevalence and Mechanisms of Fluoroquinolone Resistance.
    Yang Q; Zhao M; Wang KY; Wang J; He Y; Wang EL; Liu T; Chen DF; Lai W
    Microb Drug Resist; 2017 Jun; 23(4):473-479. PubMed ID: 27483342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in the gyrA and parC genes in Salmonella spp. following in vitro exposure to fluoroquinolones.
    Cebrian L; Escribano I; Rodriguez JC; Royo G
    J Chemother; 2006 Jun; 18(3):250-4. PubMed ID: 17129834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.